688799.SH
Hunan Warrant Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 46.25
−1.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.5B | 1.4B | 1.4B | 1.3B |
| Cost of Revenue | 612.4M | 597.4M | 542.1M | 504.6M | 417.4M |
| Gross Profit | 880.1M | 906.8M | 870.8M | 928.2M | 875.3M |
| Operating Expenses | |||||
| R&D Expense | 124.3M | 129.9M | 158.3M | 103.2M | 88.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 122.3M | 121.2M | 66.9M | 67.2M | 48.7M |
| Selling & Marketing Expense | 479.9M | 496.6M | 480.4M | 528.1M | 547.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 745.6M | 762.3M | 714.2M | 705.5M | 693.9M |
| Cost and Expenses | 1.4B | 1.4B | 1.3B | 1.2B | 1.1B |
| Operating Income (EBIT) | 227.1M | 240.5M | 161.8M | 237.1M | 196.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 227.5M | 240.9M | 161.7M | 229.9M | 195.0M |
| Income Tax Expense | 9.8M | 12.8M | 22.9M | 36.8M | 21.6M |
| Bottom Line | |||||
| Net Income | 223.9M | 238.3M | 164.3M | 211.3M | 182.8M |
| Earnings from Cont. Ops | 217.7M | 228.1M | 138.8M | 193.0M | 173.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 223.9M | 238.3M | 164.3M | 211.3M | 182.8M |
| Per Share | |||||
| Basic EPS | CN¥1.70 | CN¥1.81 | CN¥1.25 | CN¥2.25 | CN¥1.95 |
| Diluted EPS | CN¥1.70 | CN¥1.77 | CN¥1.25 | CN¥2.25 | CN¥1.95 |
| Revenue Per Share | CN¥11.11 | CN¥11.43 | CN¥10.75 | CN¥15.26 | CN¥13.79 |
| Shares | |||||
| Basic Shares Outstanding | 134.4M | 131.6M | 131.5M | 93.9M | 93.7M |
| Diluted Shares Outstanding | 134.4M | 131.6M | 131.5M | 93.9M | 93.7M |
| Profitability Metrics | |||||
| EBITDA | — | 317.3M | 233.9M | 299.4M | 245.3M |
| D&A | — | 76.8M | 72.1M | 62.3M | 49.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026